Competing clinical trials in the same institution: Ethical issues in subject selection and informed consent

IRB Ethics and Human Research

Volumn 24, Issue 2, 2002, Pages 1-7

  Gordon, Elisa J ^a   Micetich, Kenneth C ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOMEDICAL AND BEHAVIORAL RESEARCH; CLINICAL TRIAL; HUMAN; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; PATIENT SELECTION; PROFESSIONAL STANDARD; RESEARCH SUBJECT;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

CLINICAL TRIALS; DISCLOSURE; ETHICS COMMITTEES, RESEARCH; HUMANS; INFORMED CONSENT; PATIENT SELECTION; RESEARCH SUBJECTS;

EID: 11244250696     PISSN: 01937758     EISSN: None     Source Type: Journal    
DOI: 10.2307/3563649     Document Type: Article

References (38)

1. Ashcroft RE, Chadwick DW, Clark SRL, et al. Implications of socio-cultural contexts for the ethics of clinical trials. Health Technology Assessment 1997; 1(9):1-65.
2. Appelbaum PS, Lidz CW, Meisel A. Informed Consent: Legal Theory and Clinical Practice. New York: Oxford University Press, 1987:54.
3. Taylor KM, Feldstein ML, Skeel RT, et al. Fundamental dilemmas of the randomized clinical trial process: Results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators. Journal of Clinical Oncology 1994;12(9):1796-805.
4. Prillaman HL. A physician's duty to inform of newly developed therapy. Journal of Contemporary Health Law & Policy 1990;6:43-58, 51.
5. Terrion HF. Informed choice: Physicians' duty to disclose nonreadily available alternatives. Case Western Reserve Law Review 1993;43(2):491-523.
6. See ref. 5, Terrion 1993:494.
7. Freedman B. Equipoise and the ethics of clinical research. New England Journal of Medicine 1987;317(3):141-5; Weijer C, Shapiro S, Glass K, Enkin M. For and against: Clinical equipoise and not the uncertainty principle is the moral underpinning of the randomised controlled trial. British Medical Journal 2000;321:756-58.
8. Freedman B. Equipoise and the ethics of clinical research. New England Journal of Medicine 1987;317(3):141-5; Weijer C, Shapiro S, Glass K, Enkin M. For and against: Clinical equipoise and not the uncertainty principle is the moral underpinning of the randomised controlled trial. British Medical Journal 2000;321:756-58.
9. See ref. 7, Weijer et al. 2000:756.
10. Faden RR, Beauchamp TL, King NMP. A History and Theory of Informed Consent. New York: Oxford University Press, 1986.; Veatch RM. Abandoning informed consent. Hastings Center Report 1995;25(2):5-12.
11. Faden RR, Beauchamp TL, King NMP. A History and Theory of Informed Consent. New York: Oxford University Press, 1986.; Veatch RM. Abandoning informed consent. Hastings Center Report 1995;25(2):5-12.
12. Bok S. Shading the truth in seeking informed consent for research purposes. Kennedy Institute of Ethics Journal 1995;5(1):1-17.
13. King NMP. Experimental treatment: Oxymoron or aspiration? Hastings Center Report 1995;25(4):6-15, 9.
14. See ref. 9, Faden et al. 1986; Veatch 1995.
15. Siminoff LA, Fetting JH, Abeloff MD. Doctor-patient communication about breast cancer adjuvant therapy. Journal of Clinical Oncology 1989;7(9):1192-1200.
16. Kahn JP, Mastroianni AC, and Sugarman J, eds. Beyond Consent: Seeking Justice in Research. New York: Oxford University Press, 1998.
17. See ref. 14, Kahn et al. 1998.
18. Daugherty CK, Siegler M, Ratain MJ, Zimmer G. Learning from our patients: One participant's impact on clinician trial research and informed consent. Annals of Internal Medicine 1997;126(11):892-97.
19. Daugherty CK, Ratain MJ, Minami H, et al. Study of cohort-specific consent and patient control in phase I cancer trials. Journal of Clinical Oncology 1998;16(7):2305-12.
20. Crouch RA. Eligibility, extrapolation & equipoise: Unlearned lessons in the ethical analysis of clinical research [Insight]. IRB 2001;23(4):6-9. See also Freedman B. Scientific value and validity as ethical requirements for research: A proposed explication. IRB 1987;9(6):7-10.
21. Crouch RA. Eligibility, extrapolation & equipoise: Unlearned lessons in the ethical analysis of clinical research [Insight]. IRB 2001;23(4):6-9. See also Freedman B. Scientific value and validity as ethical requirements for research: A proposed explication. IRB 1987;9(6):7-10.
22. McQuellon RP, Muss HB, Hoffman SL, et al. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. Journal of Clinical Oncology 1995;13(4):858-68.
23. Stefanek M, Enger C, Benkendorf J, Flamm HS, Lerman C. Bilateral prophylactic mastectomy decision making: A vignette study. Preventive Medicine 1999;29(3): 216-21.
24. Llewellyn-Thomas HA, McGreal J, Theil EC. Cancer patients' decision making and trial-entry preferences: The effects of "framing" information about short-term toxicity and long-term survival. Medical Decision Making 1995;15:4-12.
25. Siminoff LA, Petting JH. Factors affecting treatment decisions for a life-threatening illness: The case of medical treatment of breast cancer. Social Science and Medicine 1991;32(7):813-18.
26. Hux J, Naylor CD. Does the format of efficacy data determine patients' acceptance of treatment? Medical Decision Making 1995;15:152-59.
27. Ubel PA. Is information always a good thing? Helping patients make "good" decisions. Medical Car;e in review.
28. Shafir E. Choosing versus rejecting: Why some options are both better and worse than others. Memory and Cognition 1993;21:546-556.
29. See ref. 13, Siminoff et al. 1989.
30. Daugherty CK, Banik DM, Janish L, Ratain MJ. Quantitative analysis of ethical issues in phase I trials: A survey interview study of 144 advanced cancer patients. IRB 2000;22(3):6-14.
31. Penman DT, Holland JT, Bahna GF, et al. Informed consent for investigational chemotherapy: Patients' and physicians' perceptions. Journal of Clinical Oncology 1984;2(7):849-55.
32. Llewellyn-Thomas HA, McGreal MJ, Thiel EC. Fine S, Erlichman C. Patients' willingness to enter clinical trials: Measuring the association with perceived benefit and preference for decision participation. Social Science and Medicine 1991; 32:35-42.
33. Fetting JH, Siminoff LA, Piantadosi S, et al. Effect of patients' expectations of benefit with standard breast cancer adjuvant chemotherapy on participation in a randomized clinical trial: A clinical vignette study. Journal of Clinical Oncology 1990;8(9):1476-82.
34. Silverman H, Hull SC, Sugarman J. Variability among institutional review boards' decisions within the context of a multicenter trial. Critical Care Medicine 2001;29(2):235-41.
35. Rogers AS, Schwartz DF, Weissman G, English A. A case study in adolescent participation in clinical research: Eleven clinical sites, one common protocol, and eleven IRBs. IRB 1999:21:6-10.
36. Anderlik MR, Elster N. Lawsuits against IRBs: Accountability or incongruity? Journal of Law, Medicine & Ethics 2001;29(2):220-28.
37. See ref. EJ, Terrion 1993.
38. Gordon EJ, Daugherty CK. Referral and decision making among advanced cancer patients participating in phase I trials at a single institution. Journal of Clinical Ethics 2001;12:19-26.